Taking a light approach to treating acute ischemic stroke patients: Transcranial near-infrared laser therapy translational science
- 1 October 2010
- journal article
- review article
- Published by Informa UK Limited in Annals of Medicine
- Vol. 42 (8), 576-586
- https://doi.org/10.3109/07853890.2010.532811
Abstract
Transcranial near-infrared laser therapy (NILT) has been investigated as a novel neuroprotective treatment for acute ischemic stroke (AIS), for approximately 10 years. Two clinical trials, NeuroThera Effectiveness and Safety Trial (NEST)-1 and NEST-2, have evaluated the use of NILT to promote clinical recovery in patients with AIS. This review covers preclinical, translational, and clinical studies documented during the period 1997–2010. The primary aim of this article is to detail the development profile of NILT to treat AIS. Secondly, insight into possible mechanisms involved in light therapy will be presented. Lastly, possible new directions that should be considered to improve the efficacy profile of NILT in AIS patients will be discussed. The use of NILT was advanced to clinical trials based upon extensive translational research using multiple species. NILT, which may promote functional and behavioral recovery via a mitochondrial mechanism and by enhancing cerebral blood flow, may eventually be established as an Food and Drug Administration (FDA)-approved treatment for stroke. The NEST-3 trial, which is the pivotal trial for FDA approval, should incorporate hypotheses derived from translational studies to ensure efficacy in patients. Future NILT studies should consider administration of a thrombolytic to enhance cerebral reperfusion alongside NILT neuroprotection.Keywords
This publication has 60 references indexed in Scilit:
- A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbitsBrain Research, 2010
- Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy DevelopmentTranslational Stroke Research, 2010
- Recombinant Human Erythropoietin in the Treatment of Acute Ischemic StrokeStroke, 2009
- Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic StrokeStroke, 2009
- Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour WindowStroke, 2009
- Treatment effects for which shift or binary analyses are advantageous in acute stroke trialsNeurology, 2009
- Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic StrokeStroke, 2009
- Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicityNeuroscience, 2008
- Low-Level Laser Therapy Applied Transcranially to Rats After Induction of Stroke Significantly Reduces Long-Term Neurological DeficitsStroke, 2006
- Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic StrokeStroke, 2000